TPO and hypothyroidism: In the same cohort, one patient who underwent all three [89Zr]Zr-durvalumab tracer administrations, developed hypothyroidism with thyroperoxidase antibodies, most likely due to an immune-related thyroiditis, see figure 2B–E.